HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $5 Price Target

Benzinga ·  May 10 08:21

HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment